Premium
Prognosis of breast‐carcinoma lymphagenesis evaluated by immunohistochemical investigation of vascular‐endothelial‐growth‐factor receptor 3
Author(s) -
Jacquemier Jocelyne,
MathoulinPortier MariePierre,
Valtola Reija,
CharafeJauffret Emmanuelle,
Geneix Jeannine,
Houvenaeghel Gilles,
Puig Brigitte,
Bardou ValérieJeanne,
Hassoun Jacques,
Viens Patrice,
Birnbaum Daniel
Publication year - 2000
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/(sici)1097-0215(20000120)89:1<69::aid-ijc11>3.0.co;2-m
Subject(s) - medicine , breast carcinoma , lymph node , immunohistochemistry , lymphatic system , pathology , breast cancer , vascular endothelial growth factor , monoclonal antibody , antigen , oncology , antibody , vegf receptors , cancer , immunology
Very few studies have yet addressed the question of the existence and role of lymphagenesis in tumor growth; it is generally overshadowed by the greater emphasis placed on the blood vascular system. Monoclonal antibodies against vascular endothelial‐growth‐factor receptor 3 (VEGFR3) have been shown to provide a specific antigenic marker for lymphatic endothelium. By comparison with the microvascular count (MVC), we investigated the prognostic value of the microlymphatic count (MLC) in a series of 60 cases of 2‐cm‐diameter breast carcinomas. The mean value of MVC was 72.5 and of MLC, 40.5. There was no quantitative correlation between these 2 parameters. The MVC but not the MLC had a prognostic value in overall survival. Neither the MLC nor the MVC had any correlation with axillary‐lymph‐node invasion. Int. J. Cancer (Pred. Oncol.) 89:69–73, 2000. © 2000 Wiley‐Liss, Inc.